Veselovska N.M.^1, 2, Zherebko I.B.^1, 2, Kuchar N.V.^1, 2
1Kyiv City Ophthalmologic Center, Kyiv City Clinical Hospital № 1, Kyiv, Ukraine
²Kyiv Medical University of UAFM, Kyiv, Ukraine

SUMMARY

Problem. According to current observations, the increase in free cholesterol, low density lipoprotein and triglyceride levels associated with the risk of diabetic macular edema (DME).

Purpose. To study the effectiveness of pharmacological micronized fenofibrate, 145 mg in the complex treatment of patients with type II diabetes with diabetic macular edema.

Material and methods. Two groups of patients with diabetes type II and DME were investigated. In first group patients received the fenofibrate, 145 mg during 8 months and onetime intraocular injection of aflіbersept; in the second one – only intraocular injection of aflіbersept. Assessment of the retina produced in all terms by visual acuity and retinal thickness of macular area with optical coherence tomography Stratus-3000 with control of the lipid parameters in blood serum.

Results. In 8 months in group I, who obtained the drug fenofibrate, 145 mg, marked and more positive trend in ophthalmic and biochemical parameters and improve lipid profile were revealed.

Conclusion. The paper presents the results of the comparative analysis to determine the effectiveness of micronized fenofibrate (Traykor®145 mg) in complex microsurgical treatment of DME with the control of the dynamics of changes in lipid parameters of blood serum was done.

Keywords: diabetes, macular edema, blood lipid fractions.

REFERENCES
1. Arbeneva N. S., Patrina V. V., Bratko G. V., Chernykh V. V., Sazonova O. V. Experience of micronized fenofibrate in the proliferative diabetic retinopathy. Vestnik Novosibirskogo gosudarstvennogo universiteta [Bulletin of the Novosibirsk State University]. 2011; (4): 11–14 (in Russian).
2. Balashevich L. I., Izmaylov A. S., Brzheskiy V. V. Ocular manifestations of diabetes. Saint Petersburg, MAPO, 2004, pp. 123–199 (in Russian).
3. Veselovska N. M. Risk factors for vascular pathology of eye in patients with diabetes. Klinichna endokrynolohiia ta endokrynna khirurhiia [Clinical Endocrinology and Endocrine Surgery]. 2013; (1): 42–46 (in Ukrainian).
4. Klein R., Klein B. E., Moss S. E., Davis M. D., DeMets D. L. The Wisconsin epidemiologic study of Diabetic Retinopathy II, III. Archives of Ophthalmology. 1984; (102): 50–56.
5. Porta M., Bandello F. Diabetic retinopathy: a clinical update. Diabetologia. 2002; (45): 1617–1634.
6. Klein R., Klein B. E., Moss S. E., Cruickshanks K. J. The Wisconsin epidemiologic study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type I diabetes. Ophthalmology. 1998; (105): 1801–1815.
7. Chaturvedi N., Sjolie A. K., Stephenson J. M., Abrahamian H., Keipes M., Castellarin A., Rogulja-Pepeonik Z., Fuller J. H. Effect of lisinopril on progression of retinopathy in normotensive people with type I diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin Dependent Diabetes Mellitus. Lancet. 1998; (351): 28–31.
8. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study. XII: Differences between Asian, Afro-Caribbean and white Caucasian type 2 diabetic patients at diagnosis of diabetes. Diabetes Medicine. 1994; (11): 670–677.
9. Klein B. E., Moss S. E., Klein R., Surawicz T. S. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology. 1991; (98): 1261–1265.
10. Early Treatment Diabetes Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. Ophthalmology. 1991; (98): 1262–1265.
11. Oksman P., Keinanen-Kiukaanniemi S., Laatikainen L. Prevalence and risk factors of diabetic retinopathy according to type of treatment in type II diabetic patients. Investigative Ophthalmology & Visual Science. 1995; (36): 1000.
12. Stephenson J. M., Fuller J. H., Viberti G. C., Sjolie A.-K. Blood pressure, retinopathy and urinary albumin excretion in IDDM: the EURODIAB IDDM Complications Study. Diabetologia. 1995; (38): 599–603.
13. Keating G. M., Croom K. F. Fenofibrate. A Review of its Use in Primary Dyslipidaemia, the Metabolic Syndrome and Type 2 Diabetes mellitus. Drugs. 2007; (67): 121–153.
14. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes; The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001; (357): 905–910.
15. Wright A. D., Dodson P. M. Medical management of diabetic retinopathy fenofibrate and ACCORD Eye studies. Eye. 2011; (25): 843–849.
16. Keech A. C., Mitchell P., Summanen P. A., O’Day J., Davis T. M., Moffitt M. S., Taskinen M. R., Simes R. J., Tse D., Williamson E., Merrifield A., Laatikainen L. T., d’Emden M. C., Crimet D. C., O’Connell R. L., Colman P. G. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007; (370): 1687–1697.

21.04.2015